Cempra, Inc. (NASDAQ:CEMP) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday.

According to Zacks, “Cempra Holdings, LLC is a pharmaceutical company engaged in developing antibiotics for the treatment of bacterial infectious diseases. It focuses on developing antibiotics for treating respiratory tract, skin and skin structure infections and to target the growing problem of antimicrobial resistance. Cempra Holdings, LLC is headquartered in Chapel Hill, North Carolina. “

A number of other research analysts have also issued reports on the company. Vetr upgraded Cempra from a “buy” rating to a “strong-buy” rating and set a $4.86 target price on the stock in a research report on Monday, May 1st. Jefferies Group LLC reiterated a “hold” rating and set a $3.00 target price on shares of Cempra in a research report on Thursday, May 25th. ValuEngine lowered Cempra from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Roth Capital lowered Cempra from a “buy” rating to a “neutral” rating and decreased their target price for the company from $8.00 to $4.00 in a research report on Thursday. Finally, Stifel Nicolaus reiterated a “hold” rating and set a $4.00 target price on shares of Cempra in a research report on Thursday. Four equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Cempra presently has an average rating of “Hold” and an average price target of $11.38.

Cempra (NASDAQ:CEMP) remained flat at $3.20 during trading on Monday. The company’s stock had a trading volume of 1,040,395 shares. The company has a 50-day moving average of $4.17 and a 200 day moving average of $3.83. Cempra has a 52 week low of $2.55 and a 52 week high of $26.95. The stock’s market capitalization is $168.02 million.

Cempra (NASDAQ:CEMP) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.09. Cempra had a negative return on equity of 53.99% and a negative net margin of 560.40%. The firm had revenue of $0.86 million for the quarter, compared to analyst estimates of $3.58 million. During the same quarter last year, the firm posted ($0.51) EPS. The business’s revenue was down 74.9% on a year-over-year basis. Analysts predict that Cempra will post ($1.00) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/14/cempra-inc-cemp-downgraded-by-zacks-investment-research-to-hold.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Voya Investment Management LLC raised its position in shares of Cempra by 34.1% in the second quarter. Voya Investment Management LLC now owns 23,006 shares of the biotechnology company’s stock worth $106,000 after buying an additional 5,848 shares during the last quarter. Janney Montgomery Scott LLC raised its position in shares of Cempra by 35.6% in the second quarter. Janney Montgomery Scott LLC now owns 25,900 shares of the biotechnology company’s stock worth $119,000 after buying an additional 6,800 shares during the last quarter. Asset Management One Co. Ltd. purchased a new position in shares of Cempra during the first quarter worth $106,000. LMR Partners LLP purchased a new position in shares of Cempra during the second quarter worth $149,000. Finally, Ameriprise Financial Inc. purchased a new position in shares of Cempra during the second quarter worth $164,000. Institutional investors own 52.39% of the company’s stock.

Cempra Company Profile

Cempra, Inc is a clinical-stage pharmaceutical company. The Company focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. Its product, solithromycin (CEM-101), which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

Get a free copy of the Zacks research report on Cempra (CEMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Cempra (NASDAQ:CEMP)

Receive News & Ratings for Cempra Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cempra Inc. and related companies with MarketBeat.com's FREE daily email newsletter.